Two izoenzymes of cyclooxygenase, COX-1 and COX-2, are proven to catalyze the rate-limiting step in prostaglandin synthesis. This enzyme is the target of nonsteroidal anti-inflammatory drugs, mainly Acetaminophen.
Cyclooxygenase-2, COX-2, is overexpressed in colon cancer, suggesting a relationship between the pathway and signaling of COX-2 and colorectal carcinogens. When COX-2 activity is inhibited by sulindac, a metabolite of sulindac sulfoxide, the average diameter and number of polyps decreased in patients affected by colorectal cancers.
The role of cyclooxygenase-2 in Colon Cancer. 
COX-3: Cloning, Structure, and Expression 
Variants of cyclooxygenase-1 and their roles in medicine. 
See Help:References for how to manage references in GONUTS.
- Eisinger, AL et al. (2007) The role of cyclooxygenase-2 and prostaglandins in colon cancer. Prostaglandins Other Lipid Mediat. 82 147-54 PubMed GONUTS page
- Chandrasekharan, NV et al. (2002) COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc. Natl. Acad. Sci. U.S.A. 99 13926-31 PubMed GONUTS page
- Simmons, DL (2003) Variants of cyclooxygenase-1 and their roles in medicine. Thromb. Res. 110 265-8 PubMed GONUTS page